Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $414 from $408 and keeps an Equal Weight rating on the shares. The company reported a slight beat in Q3 with a slight raise to the lower end of its revenue guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Reports Strong Q3 2025 Results
- Closing Bell Movers: Palantir down 3% after earnings
- Vertex Pharmaceuticals reports Q3 adjusted EPS $4.80, consensus $4.58
- Vertex options imply 6.1% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, November 03, 2025